Medline, one of the largest suppliers of medical products in the U.S., has filed for an initial public offering (IPO) of its common stock.
The decision to go public comes after several years of continued growth for the company. Last year, Medline totaled $25.5 billion in net sales after hitting $23.2 billion in 2023 and $21.4 billion in 2022. During that same time period, the company has seen its net income swing from a $25 million loss in 2022 to a $1.2 billion gain in 2024.
Medline's operations include 33 manufacturing facilities and 69 distribution centers that cover around 335,000 different medical products, the majority of which are available for next-day delivery to U.S. customers thanks to an owned fleet of more than 2,000 MedTrans trucks. The company has more than 43,000 employees worldwide.
Medline's two segments, Medline Brand and Supply Chain Solutions, offer products including surgical and procedural kits; gloves and protective apparel; urological and incontinence care; wound care; and consumable lab and diagnostics products.
If the offering is completed, Medline intends to list its stock on the Nasdaq Global Select Market under the symbol “MDLN.”
